<img height="1" width="1" style="display:none;" alt="" src="https://dc.ads.linkedin.com/collect/?pid=311073&amp;fmt=gif">

MedTech Roundup

learn more about trends, news and advancements in the MedTech space

Novasyte to Exhibit at Eye for Pharma's Patient Summit 2018

Posted by Steven Saminathen on Oct 4, 2018 8:40:00 AM

The Novasyte Pharma Services Team will be attending and exhibiting at Eye for Pharma Patient Summit 2018 on Tuesday, October 23rd through Wednesday, October 24th at the Sonesta Hotel in Philadelphia. 

Read More

Topics: Novasyte News, Novasyte Partnership, Medical Device Industry, Contract Clinical, Pharmaceutical Industry

Novasyte Recognized Among Only Six Percent of Companies Making the Inc. 5000 List for Six Consecutive Years

Posted by Charlotte Morello on Aug 15, 2018 6:03:00 AM

Novasyte is honored to announce that we ranked 1,692 overall and 125 in the healthcare category on the 2018 Inc. 5000 List of Fastest-Growing Private Companies in America. This marks the sixth consecutive year achieving this recognition, putting us on an exclusive short list of only six percent of companies acknowledged for maintaining this level of continued growth over the years, including Microsoft, Timberland, Vizio, Intuit, Chobani, Oracle and Zappos.com. 

Read More

Topics: Novasyte News, Business Awards, Novasyte Growth, Leadership News, Medical Device Industry, San Diego, CA, Pharmaceutical Industry

Pressures Mount for Drug Manufacturers to Reduce Cost, Forcing Reevaluation of SG&A Costs and Commercial Models

Posted by Charlotte Morello on Jul 20, 2018 1:40:42 PM

Pharmaceutical manufacturers today are facing increasing pressures from The Trump Administration to reduce the cost of drug prices.

Announced on Wednesday of this week, Novartis indicated they would not be raising prices on its products for the remainder of 2018.They are joining Pfizer, whose chief executive officer, Ian Read, announced on July 10 that the company would delay increasing the prices on dozens of drug products until 2019, following President Trump publicly spotlighting the firm the day prior.2

This follows the initial statement from The Trump Administration in May 2018 regarding a comprehensive blueprint strategy to lower drug prices.

Read More

Topics: Industry Trends, Pharmaceutical Industry